Item 8.01.Other Events. On March 17, 2023, Acer Therapeutics Inc. issued a press release entitled “Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial,” a copy of which is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01.Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Acer Therapeutics Inc. dated March 17, 2023, entitled “Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial.” 104 Cover page interactive data file (embedded within the inline XBRL document). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the re(…)
The Latest Press Releases